Benefits of Deep Brain Stimulation for Early Stage Parkinson Disease
Compared with optimal medical therapy alone, deep brain stimulation can decrease the risk for disease progression in patients with early-stage Parkinson disease.
Parkinson Disease
The Role of Precision Medicine in Parkinson Disease
Precision medicine offers a promising therapeutic strategy for patients with Parkinson disease, allowing for tailored treatments which reflect the unique pathophysiology in each patient.
Phone-Based Therapy Beneficial for Depression in Parkinson Disease
Telephone-based cognitive behavioral therapy seems to be an effective intervention for depression in Parkinson disease, outperforming treatment-as-usual on all depression, anxiety, and quality-of-life measures.
Efficacy of Isradipine in Early-Stage Parkinson Disease
Researchers assessed the effect of isradipine on clinical progression in previously untreated patients with early-stage PD.
Abnormal Cerebral Blood Flow May Influence the Etiology of Parkinson Disease
Patients with Parkinson disease tend to have an increase in iron content with reduced perfusion in the substantia nigra.
Iron Deposition Provides Cognitive Clues in Patients With Parkinson Disease
Up to half of patients with Parkinson disease are also diagnosed with dementia, but tools to track changes in cognition are lacking.
Possible Molecular Signature for Young-Onset Parkinson Disease Identified
There is a distinct genetic signature for young-onset Parkinson disease even in cells from those who have no known Parkinson disease-related mutations.
Bipolar Disorder Associated With Increased Risk for Parkinson Disease
Compared with the general population, patients with bipolar disorder have an increased risk of developing idiopathic Parkinson disease.
Is There a Link Between Drugs for Parkinson Disease and Gambling Disorders?
Pathological gambling was recently identified as a complication of Parkinson disease and its pharmacological treatment, especially high-dose dopaminergic agonists.
FDA Approves New Adjunct Treatment for Parkinson Disease
The Food and Drug Administration (FDA) has approved Nourianz (istradefylline; Kyowa Kirin) tablets as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson disease (PD) experiencing “off” episodes.
-
Loading...
-
Loading...
Next post in Medicine
